UBS O'Connor’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

UBS O'Connor’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-50,000	Closed	-$3.97M	–	840
2022 Q3	$3.97M	Buy	+50,000	New	+$4.22M	0.05%	356
2016 Q1	–	Sell	-144,434	Closed	-$7.5M	–	538
2015 Q4	$10.1M	Buy	+144,434	New	+$9.85M	0.09%	184

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

UBS O'Connor's XBI Position: Q4 2022 in Review

UBS O'Connor sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2022, closing a stake of 50,000 shares — an estimated $3.97M sold.

UBS O'Connor first reported a position in XBI in Q4 2015 and held it in 2 quarters. The position peaked at $10.1M in Q4 2015. 745 funds tracked by Wall St. Rank hold XBI as of Q4 2022.

UBS O'Connor reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2022 after selling out during the quarter.
UBS O'Connor sold 50,000 State Street SPDR S&P Biotech ETF shares in Q4 2022, an estimated $3.97M.
UBS O'Connor first reported a position in State Street SPDR S&P Biotech ETF in Q4 2015 and held it in 2 quarters.
UBS O'Connor's State Street SPDR S&P Biotech ETF position peaked at $10.1M in Q4 2015.
745 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2022.

Based on UBS O'Connor's 13F filing for Q4 2022, filed 14 Feb 2023.